<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="urn:hl7-org:v3" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="00f18845-ccdf-8678-e063-6294a90a3374"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>IOPIDINE 1% (apraclonidine hydrochloride ophthalmic solution) 1% as base Sterile</title>
   <effectiveTime value="20230731"/>
   <setId root="00f18845-ccde-8678-e063-6294a90a3374"/>
   <versionNumber value="1"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id root="1.3.6.1.4.1.519.1" extension="118526951"/>
            <name>Harrow Eye, LLC</name>
            <assignedEntity>
               <assignedOrganization/>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="01ccc08b-1d9f-35e9-e063-6294a90a63e4"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL product data elements section"/>
               <effectiveTime value="20230731"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="82667-200" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>IOPIDINE 1%</name>
                        <formCode code="C60992" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SOLUTION/ DROPS"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>apraclonidine hydrochloride ophthalmic solution</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIM">
                           <quantity>
                              <numerator unit="mg" value="10"/>
                              <denominator unit="mL" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="D2VW67N38H" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>APRACLONIDINE HYDROCHLORIDE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="843CEN85DI" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>APRACLONIDINE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="451W47IQ8X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM CHLORIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>WATER</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="QTT17582CB" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYDROCHLORIC ACID</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="F5UM2KM3W7" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>BENZALKONIUM CHLORIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="4550K0SC9B" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM ACETATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="55X04QC32I" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM HYDROXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="0.1" unit="mL"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43215" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="VIAL, SINGLE-DOSE"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="2" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code/>
                                    <formCode code="C43200" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="POUCH"/>
                                    <asContent>
                                       <quantity>
                                          <numerator value="12" unit="1"/>
                                          <denominator value="1"/>
                                       </quantity>
                                       <containerPackagedProduct>
                                          <code code="82667-200-01" codeSystem="2.16.840.1.113883.6.69"/>
                                          <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                       </containerPackagedProduct>
                                       <subjectOf>
                                          <marketingAct>
                                             <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                             <statusCode code="active"/>
                                             <effectiveTime>
                                                <low value="20230801"/>
                                             </effectiveTime>
                                          </marketingAct>
                                       </subjectOf>
                                    </asContent>
                                 </containerPackagedProduct>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA019779" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20230801"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38287" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="OPHTHALMIC"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="id_link_00f1af3d-40ef-68c3-e063-6394a90aeac0">
               <id root="01cb4e93-36e1-5f81-e063-6394a90a5a6a"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <text>
                  <paragraph>IOPIDINE 1% Ophthalmic Solution contains apraclonidine hydrochloride, an alpha adrenergic agonist, in a sterile isotonic solution
  <br/>
for topical application to the eye. Apraclonidine hydrochloride is a white to offâ€‘white powder and is highly soluble in water. Its chemical name is 2-[(4â€‘amino-2,6 dichlorophenyl)imino] imidazolidine monohydrochloride with an empirical formula of C
  <sub>9</sub>H
  <sub>11</sub>Cl
  <sub>3</sub>N
  <sub>4</sub> and a molecular weight of 281.6. The chemical structure of apraclonidine hydrochloride is:
 </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="img_00f1bd10-95a1-1918-e063-6294a90a28c9"/>
                     <br/>
Each mL of IOPIDINE 1% Ophthalmic Solution contains:
 </paragraph>
                  <paragraph>
                     <content styleCode="bold">Actives</content>: apraclonidine hydrochloride 11.5 mg equivalent to apraclonidine base
  <br/>
10 mg.
 </paragraph>
                  <paragraph>
                     <content styleCode="bold">Inactives:</content> sodium chloride, sodium acetate, sodium hydroxide and/or hydrochloric acid (pH 4.4â€‘7.8), purified water and benzalkonium
  <br/>
chloride 0.01% (preservative). Osmolality is 260â€‘320 mOsm.
 </paragraph>
               </text>
               <effectiveTime value="20230731"/>
               <component>
                  <observationMedia ID="img_00f1bd10-95a1-1918-e063-6294a90a28c9">
                     <text>Picture1</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="Picture1.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="id_link_00f1ac7a-2af1-665a-e063-6394a90aca9f">
               <id root="01cb584f-4549-a2ad-e063-6394a90a8647"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <text>
                  <paragraph>Apraclonidine is a relatively selective, alpha adrenergic agonist and does not have significant membrane stabilizing (local anesthetic) activity. When instilled into the eye, IOPIDINE 1% (apraclonidine hydrochloride ophthalmic solution) has the action of reducing intraocular pressure (IOP). Ophthalmic apraclonidine has minimal effect on cardiovascular parameters.</paragraph>
                  <paragraph>Optic nerve head damage and visual field loss may result from an acute elevation in IOP that can occur after argon or Nd:YAG laser surgical procedures. Elevated IOP, whether acute or chronic in duration, is a major risk factor in the pathogenesis of visual field loss. The higher the peak or spike of IOP, the greater the likelihood of visual field loss and optic nerve damage especially in patients with previously compromised optic nerves. The onset of action with IOPIDINE 1% Ophthalmic Solution can usually be noted within one hour and the maximum IOP reduction usually occurs three to five hours after application of a single dose. The precise mechanism of the ocular hypotensive action of IOPIDINE 1% Ophthalmic Solution is not completely established at this time. Aqueous fluorophotometry studies in man suggest that its predominant action may be related to a reduction of aqueous formation. Controlled clinical studies of patients requiring argon laser trabeculoplasty, argon laser iridotomy or Nd:YAG posterior capsulotomy showed that IOPIDINE 1% Ophthalmic Solution controlled or prevented the post-surgical IOP rise typically observed in patients after undergoing those procedures. After surgery, the mean IOP was 1.2 to 4 mmHg below the corresponding pre-surgical baseline pressure before IOPIDINE Ophthalmic Solution treatment. With placebo treatment, post-surgical pressures were 2.5 to 8.4 mmHg higher than their corresponding pre-surgical baselines. Overall, only 2% of patients treated with IOPIDINE* 1% Ophthalmic Solution had severe IOP elevations (spike greater than or equal to 10 mmHg) during the first three hours after laser surgery, whereas 23% of placebo-treated patients responded with severe pressure spikes (Table 1). Of the patients that experienced a pressure spike after surgery, the peak IOP was above 30 mmHg in most patients (Table 2) and was above 50 mmHg in seven placebo-treated patients and one IOPIDINE 1% Ophthalmic Solution-treated patient.</paragraph>
                  <paragraph/>
                  <paragraph>
                     <content styleCode="bold">Table 1: Incidence of IOP Spikes Greater Than or Equal to 10 mmHg</content>
                  </paragraph>
                  <table border="1" cellpadding="0" cellspacing="0">
                     <tbody>
                        <tr>
                           <td rowspan="3">
                              <paragraph/>
                              <paragraph>Study</paragraph>
                           </td>
                           <td rowspan="3">
                              <paragraph/>
                              <paragraph>Laser Procedure</paragraph>
                           </td>
                           <td colspan="5">
                              <paragraph>Treatment</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td>
                              <paragraph/>
                           </td>
                           <td colspan="2">
                              <paragraph>Apraclonidine</paragraph>
                           </td>
                           <td colspan="2">
                              <paragraph>Placebo</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td>
                              <paragraph>Pâ€‘Value</paragraph>
                           </td>
                           <td>
                              <paragraph>
                                 <sup>a</sup>N
     </paragraph>
                           </td>
                           <td>
                              <paragraph>(%)</paragraph>
                           </td>
                           <td>
                              <paragraph>
                                 <sup>a</sup>N
     </paragraph>
                           </td>
                           <td>
                              <paragraph>(%)</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td>
                              <paragraph>1</paragraph>
                           </td>
                           <td>
                              <paragraph>Trabeculoplasty</paragraph>
                           </td>
                           <td>
                              <paragraph>&lt;0.05</paragraph>
                           </td>
                           <td>
                              <paragraph>0/40</paragraph>
                           </td>
                           <td>
                              <paragraph>(0%)</paragraph>
                           </td>
                           <td>
                              <paragraph>6/35</paragraph>
                           </td>
                           <td>
                              <paragraph>(17%)</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td>
                              <paragraph>2</paragraph>
                           </td>
                           <td>
                              <paragraph>Trabeculoplasty</paragraph>
                           </td>
                           <td>
                              <paragraph>=0.06</paragraph>
                           </td>
                           <td>
                              <paragraph>2/41</paragraph>
                           </td>
                           <td>
                              <paragraph>(5%)</paragraph>
                           </td>
                           <td>
                              <paragraph>8/42</paragraph>
                           </td>
                           <td>
                              <paragraph>(19%)</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td>
                              <paragraph/>
                           </td>
                           <td>
                              <paragraph/>
                           </td>
                           <td>
                              <paragraph/>
                           </td>
                           <td>
                              <paragraph/>
                           </td>
                           <td>
                              <paragraph/>
                           </td>
                           <td>
                              <paragraph/>
                           </td>
                           <td>
                              <paragraph/>
                           </td>
                        </tr>
                        <tr>
                           <td>
                              <paragraph>1</paragraph>
                           </td>
                           <td>
                              <paragraph>Iridotomy</paragraph>
                           </td>
                           <td>
                              <paragraph>&lt;0.05</paragraph>
                           </td>
                           <td>
                              <paragraph>0/11</paragraph>
                           </td>
                           <td>
                              <paragraph>(0%)</paragraph>
                           </td>
                           <td>
                              <paragraph>4/10</paragraph>
                           </td>
                           <td>
                              <paragraph>(40%)</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td>
                              <paragraph>2</paragraph>
                           </td>
                           <td>
                              <paragraph>Iridotomy</paragraph>
                           </td>
                           <td>
                              <paragraph>=0.05</paragraph>
                           </td>
                           <td>
                              <paragraph>0/17</paragraph>
                           </td>
                           <td>
                              <paragraph>(0%)</paragraph>
                           </td>
                           <td>
                              <paragraph>4/19</paragraph>
                           </td>
                           <td>
                              <paragraph>(21%)</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td>
                              <paragraph/>
                           </td>
                           <td>
                              <paragraph/>
                           </td>
                           <td>
                              <paragraph/>
                           </td>
                           <td>
                              <paragraph/>
                           </td>
                           <td>
                              <paragraph/>
                           </td>
                           <td>
                              <paragraph/>
                           </td>
                           <td>
                              <paragraph/>
                           </td>
                        </tr>
                        <tr>
                           <td>
                              <paragraph>1</paragraph>
                           </td>
                           <td>
                              <paragraph>Nd:YAG Capsulotomy</paragraph>
                           </td>
                           <td>
                              <paragraph>&lt;0.05</paragraph>
                           </td>
                           <td>
                              <paragraph>3/80</paragraph>
                           </td>
                           <td>
                              <paragraph>(4%)</paragraph>
                           </td>
                           <td>
                              <paragraph>19/83</paragraph>
                           </td>
                           <td>
                              <paragraph>(23%)</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td>
                              <paragraph>2</paragraph>
                           </td>
                           <td>
                              <paragraph>Nd:YAG Capsulotomy</paragraph>
                           </td>
                           <td>
                              <paragraph>&lt;0.05</paragraph>
                           </td>
                           <td>
                              <paragraph>0/83</paragraph>
                           </td>
                           <td>
                              <paragraph>(0%)</paragraph>
                           </td>
                           <td>
                              <paragraph>22/81</paragraph>
                           </td>
                           <td>
                              <paragraph>(27%)</paragraph>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>
                     <sup>a</sup>N = Number Spikes/Number Eyes.
 </paragraph>
                  <paragraph/>
                  <paragraph/>
                  <paragraph>
                     <content styleCode="bold">Table 2: Magnitude of Post-surgical IOP in Trabeculoplasty, Iridotomy and Nd:YAG Capsulotomy Patients With Severe Pressure Spikes Greater than or Equal to 10 mmHg</content>
                  </paragraph>
                  <paragraph/>
                  <paragraph>
                     <content styleCode="underline">Maximum Postsurgical IOP (mmHg)</content>
                  </paragraph>
                  <table border="1" cellpadding="0" cellspacing="0">
                     <tbody>
                        <tr>
                           <td>
                              <paragraph>
                                 <content styleCode="bold">Treatment</content>
                              </paragraph>
                           </td>
                           <td>
                              <paragraph>
                                 <content styleCode="bold">Total</content>
                                 <content styleCode="bold">Spikes</content>
                              </paragraph>
                           </td>
                           <td>
                              <paragraph>
                                 <content styleCode="bold">20-29</content>
                                 <content styleCode="bold">mmHg</content>
                              </paragraph>
                           </td>
                           <td>
                              <paragraph>
                                 <content styleCode="bold">30-39</content>
                                 <content styleCode="bold">mmHg</content>
                              </paragraph>
                           </td>
                           <td>
                              <paragraph>
                                 <content styleCode="bold">40-49 mmHg</content>
                              </paragraph>
                           </td>
                           <td>
                              <paragraph>
                                 <content styleCode="bold">&gt; 50 mmHg</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td>
                              <paragraph>IOPIDINE</paragraph>
                           </td>
                           <td>
                              <paragraph>8</paragraph>
                           </td>
                           <td>
                              <paragraph>1</paragraph>
                           </td>
                           <td>
                              <paragraph>4</paragraph>
                           </td>
                           <td>
                              <paragraph>2</paragraph>
                           </td>
                           <td>
                              <paragraph>1</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td>
                              <paragraph>Placebo</paragraph>
                           </td>
                           <td>
                              <paragraph>78</paragraph>
                           </td>
                           <td>
                              <paragraph>16</paragraph>
                           </td>
                           <td>
                              <paragraph>47</paragraph>
                           </td>
                           <td>
                              <paragraph>8</paragraph>
                           </td>
                           <td>
                              <paragraph>7</paragraph>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph/>
               </text>
               <effectiveTime value="20230731"/>
            </section>
         </component>
         <component>
            <section ID="id_link_00f1b06e-2bec-566c-e063-6294a90a1734">
               <id root="01cc3c1a-15e4-9816-e063-6294a90ac73b"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <text>
                  <paragraph>IOPIDINE 1% Ophthalmic Solution is indicated to control or prevent
  <br/>
post-surgical elevations in IOP that occur in patients after argon laser
  <br/>
trabeculoplasty, argon laser iridotomy or Nd:YAG posterior capsulotomy.
 </paragraph>
               </text>
               <effectiveTime value="20230731"/>
            </section>
         </component>
         <component>
            <section ID="id_link_00f1af3d-40f1-68c3-e063-6394a90aeac0">
               <id root="01cc58d3-2798-0a71-e063-6294a90a261e"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <text>
                  <paragraph>IOPIDINE 1% Ophthalmic Solution is contraindicated for patients
  <br/>
receiving monoamine oxidase inhibitor therapy and for patients with
  <br/>
hypersensitivity to any component of this medication or to clonidine.
 </paragraph>
               </text>
               <effectiveTime value="20230731"/>
            </section>
         </component>
         <component>
            <section ID="id_link_00f1b9be-2db4-11d6-e063-6294a90a0ae4">
               <id root="01cc4ea0-e3e4-32f1-e063-6394a90a1375"/>
               <code code="34071-1" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS SECTION"/>
               <text>
                  <paragraph>FOR TOPICAL OPHTHALMIC USE ONLY. Not for injection or oral ingestion.</paragraph>
               </text>
               <effectiveTime value="20230731"/>
            </section>
         </component>
         <component>
            <section ID="id_link_00f1bb01-b28c-5bd2-e063-6394a90a5767">
               <id root="00f1bb01-b28b-5bd2-e063-6394a90a5767"/>
               <code code="42232-9" codeSystem="2.16.840.1.113883.6.1" displayName="PRECAUTIONS SECTION"/>
               <effectiveTime value="20230727"/>
               <component>
                  <section ID="id_link_00f1ac7a-2af3-665a-e063-6394a90aca9f">
                     <id root="01cc57e2-b188-1c43-e063-6394a90a4328"/>
                     <code code="34072-9" codeSystem="2.16.840.1.113883.6.1" displayName="GENERAL PRECAUTIONS SECTION"/>
                     <text>
                        <paragraph>Since IOPIDINE* 1% Ophthalmic Solution is a potent depressor of IOP,
  <br/>
patients who develop exaggerated reductions in IOP should be closely
  <br/>
monitored. Although the acute administration of two drops of IOPIDINE
  <br/>
1% Ophthalmic Solution has minimal effect on heart rate or blood
  <br/>
pressure in clinical studies evaluating patients undergoing anterior
  <br/>
segment laser surgery, the preclinical pharmacologic profile of this drug
  <br/>
suggests that caution should be observed in treating patients with severe
  <br/>
cardiovascular disease including hypertension. IOPIDINE 1% Ophthalmic
  <br/>
Solution should also be used with caution in patients with severe
  <br/>
coronary insufficiency, recent myocardial infarction, cerebrovascular
  <br/>
disease, chronic renal failure, Raynaudâ€™s disease or thromboangiitis
  <br/>
obliterans.
  <br/>
The possibility of a vasovagal attack occurring during laser surgery
  <br/>
should be considered and caution used in patients with history of such
  <br/>
episodes.
  <br/>
Topical ocular administration of two drops of 0.5%, 1%, and 1.5%
  <br/>
IOPIDINE Ophthalmic Solution to New Zealand Albino rabbits three times
  <br/>
daily for one month resulted in sporadic and transient instances of
  <br/>
minimal corneal cloudiness in the 1.5% group only. No histopathological changes were noted in those eyes. No adverse ocular effects were
  <br/>
observed in cynomolgus monkeys treated with two drops of 1.5%
  <br/>
IOPIDINE Ophthalmic Solution applied three times daily for three months.
  <br/>
No corneal changes were observed in 320 humans given at least one
  <br/>
dose of IOPIDINE 1% Ophthalmic Solution.
 </paragraph>
                     </text>
                     <effectiveTime value="20230731"/>
                  </section>
               </component>
               <component>
                  <section ID="id_link_00f1c145-0625-2cea-e063-6294a90a4a53">
                     <id root="01cc51ab-2222-41ec-e063-6394a90a7b8d"/>
                     <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
                     <text>
                        <paragraph>Apraclonidine can cause dizziness and somnolence. Patients who engage
  <br/>
in hazardous activities requiring mental alertness should be warned of the
  <br/>
potential for a decrease in mental alertness on the day of surgery.
 </paragraph>
                     </text>
                     <effectiveTime value="20230731"/>
                  </section>
               </component>
               <component>
                  <section ID="id_link_00f1bd10-9599-1918-e063-6294a90a28c9">
                     <id root="01cc554b-9243-d891-e063-6394a90a8450"/>
                     <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
                     <text>
                        <paragraph>Interactions with other agents have not been investigated.</paragraph>
                     </text>
                     <effectiveTime value="20230731"/>
                  </section>
               </component>
               <component>
                  <section ID="id_link_00f1baa1-af94-1648-e063-6294a90aed48">
                     <id root="01cc554b-9244-d891-e063-6394a90a8450"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <text>
                        <paragraph>No significant change in tumor incidence or type was observed
  <br/>
following two years of oral administration of apraclonidine HCl to rats
  <br/>
and mice at dosages of 1 and 0.6 mg/kg/day, up to 50 and 30 times,
  <br/>
respectively, the maximum dose recommended for human topical
  <br/>
ocular use. Apraclonidine HCl was not mutagenic in a series of in vitro
  <br/>
mutagenicity tests, including the Ames test, a mouse lymphoma forward
  <br/>
mutation assay, a chromosome aberration assay in cultured Chinese
  <br/>
hamster ovary (CHO) cells, a sister chromatid exchange assay in CHO
  <br/>
cells, and a cell transformation assay. An in vivo mouse micronucleus
  <br/>
assay conducted with apraclonidine HCl also provided no evidence of
  <br/>
mutagenicity. Reproduction and fertility studies in rats showed no adverse
  <br/>
effect on male or female fertility at a dose of 0.5 mg/kg/day (25 times the
  <br/>
maximum recommended human dose).
 </paragraph>
                     </text>
                     <effectiveTime value="20230731"/>
                  </section>
               </component>
               <component>
                  <section ID="id_link_00f1c145-0628-2cea-e063-6294a90a4a53">
                     <id root="01cc57e2-b189-1c43-e063-6394a90a4328"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <text>
                        <paragraph>Apraclonidine HCl has been shown to have an embryocidal effect in
  <br/>
rabbits when given in an oral dose of 3 mg/kg/day (150 times the
  <br/>
maximum recommended human dose). Dose related maternal toxicity
  <br/>
was observed in pregnant rats at 0.3 mg/kg/day (15 times the maximum
  <br/>
recommended human dose). There are no adequate and well controlled
  <br/>
studies in pregnant women. IOPIDINE* 1% Ophthalmic Solution should be
  <br/>
used during pregnancy only if the potential benefit justifies the potential
  <br/>
risk to the fetus.
 </paragraph>
                     </text>
                     <effectiveTime value="20230731"/>
                  </section>
               </component>
               <component>
                  <section ID="id_link_00f1b9be-2dc2-11d6-e063-6294a90a0ae4">
                     <id root="01cc5f9b-6d10-6268-e063-6394a90a14f3"/>
                     <code code="34080-2" codeSystem="2.16.840.1.113883.6.1" displayName="NURSING MOTHERS SECTION"/>
                     <text>
                        <paragraph>It is not known if topically applied IOPIDINE 1% Ophthalmic Solution is
  <br/>
excreted in human milk. Decision should be made to discontinue nursing
  <br/>
temporarily for the one day on which IOPIDINE 1% Ophthalmic Solution
  <br/>
is used.
 </paragraph>
                     </text>
                     <effectiveTime value="20230731"/>
                  </section>
               </component>
               <component>
                  <section ID="id_link_00f1b9be-2dc4-11d6-e063-6294a90a0ae4">
                     <id root="01cc6051-77c6-21ed-e063-6294a90a7990"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <text>
                        <paragraph>Safety and effectiveness in pediatric patients have not been established.</paragraph>
                     </text>
                     <effectiveTime value="20230731"/>
                  </section>
               </component>
               <component>
                  <section ID="id_link_00f1bd10-959b-1918-e063-6294a90a28c9">
                     <id root="01cc58d3-279b-0a71-e063-6294a90a261e"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <text>
                        <paragraph>No overall differences in safety or effectiveness have been observed
  <br/>
between elderly and younger patients.
 </paragraph>
                     </text>
                     <effectiveTime value="20230731"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="id_link_00f1baa1-afae-1648-e063-6294a90aed48">
               <id root="01cc635d-01e7-3699-e063-6294a90a07bc"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <text>
                  <paragraph>The following adverse events, occurring in less than 2% of patients, were
  <br/>
reported in association with the use of IOPIDINE 1% Ophthalmic Solution
  <br/>
in laser surgery: ocular injection, upper lid elevation, irregular heart rate,
  <br/>
nasal decongestion, ocular inflammation, conjunctival blanching, and
  <br/>
mydriasis.
  <br/>
The following adverse events were observed in investigational studies
  <br/>
dosing IOPIDINE 1% Ophthalmic Solution once or twice daily for up to
  <br/>
28 days in nonâ€‘laser studies:
  <br/>
                     <content styleCode="underline">Ocular</content>
                     <br/>
Conjunctival blanching, upper lid elevation, mydriasis, burning, discomfort,
  <br/>
foreign body sensation, dryness, itching, hypotony, blurred or dimmed
  <br/>
vision, allergic response, conjunctival microhemorrhage.
 </paragraph>
                  <paragraph>
                     <content styleCode="underline">Gastrointestinal</content>
                     <br/>
Abdominal pain, diarrhea, stomach discomfort, emesis
  <br/>
                     <content styleCode="underline">Cardiovascular</content>
                     <br/>
Bradycardia, vasovagal attack, palpitations, orthostatic
  <br/>
episode
  <br/>
                     <content styleCode="underline">Central Nervous System</content>
                     <br/>
Insomnia, dream disturbances, irritability, decreased libido.
  <br/>
                     <content styleCode="underline">Other</content>
                     <br/>
Taste abnormalities, dry mouth, nasal burning or dryness,
  <br/>
headache, head cold sensation, chest heaviness or burning,
  <br/>
clammy or sweaty palms, body heat sensation, shortness
  <br/>
of breath, increased pharyngeal secretion, extremity pain
  <br/>
or numbness, fatigue, paresthesia, pruritus not associated
  <br/>
with rash.
  <br/>
                     <content styleCode="underline">Clinical Practice</content>
                     <br/>
The following events have been identified during postmarketing use
  <br/>
of IOPIDINE 1% Ophthalmic Solution in clinical practice. Because they
  <br/>
are reported voluntarily from a population of unknown size, estimates
  <br/>
of frequency cannot be made. The events, which have been chosen for
  <br/>
inclusion due to either their seriousness, frequency of reporting, possible
  <br/>
causal connection to IOPIDINE 1% Ophthalmic Solution, or a combination
  <br/>
of these factors, include hypersensitivity.
 </paragraph>
               </text>
               <effectiveTime value="20230731"/>
            </section>
         </component>
         <component>
            <section ID="id_link_00f1c145-062a-2cea-e063-6294a90a4a53">
               <id root="01cc5f9b-6d11-6268-e063-6394a90a14f3"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <text>
                  <paragraph>Ingestion of IOPIDINE* 0.5% Ophthalmic Solution has been reported to
  <br/>
cause bradycardia, drowsiness, and hypothermia. Accidental or intentional
  <br/>
ingestion of oral clonidine has been reported to cause apnea, arrhythmias,
  <br/>
asthenia, bradycardia, conduction defects, diminished or absent reflexes,
  <br/>
dryness of the mouth, hypotension, hypothermia, hypoventilation,
  <br/>
irritability, lethargy, miosis, pallor, respiratory depression, sedation
  <br/>
or coma, seizure, somnolence, transient hypertension, and vomiting.
  <br/>
Treatment of an oral overdose includes supportive and symptomatic
  <br/>
therapy; a patent airway should be maintained. Hemodialysis is of limited
  <br/>
value since a maximum of 5% of circulating drug is removed.
 </paragraph>
               </text>
               <effectiveTime value="20230731"/>
            </section>
         </component>
         <component>
            <section ID="id_link_00f1c145-062c-2cea-e063-6294a90a4a53">
               <id root="01cc5f9b-6d12-6268-e063-6394a90a14f3"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <text>
                  <paragraph>One drop of IOPIDINE* 1% Ophthalmic Solution should be instilled in the
  <br/>
scheduled operative eye one hour before initiating anterior segment
  <br/>
laser surgery and a second drop should be instilled to the same eye
  <br/>
immediately upon completion of the laser surgical procedure. Use
  <br/>
a separate container for each singleâ€‘drop dose and discard each
  <br/>
container after use.
 </paragraph>
               </text>
               <effectiveTime value="20230731"/>
            </section>
         </component>
         <component>
            <section ID="id_link_00f1d33a-fed2-e888-e063-6294a90aff06">
               <id root="01cc6652-76db-35bd-e063-6294a90a4dde"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <text>
                  <paragraph>IOPIDINE 1% Ophthalmic Solution as base is a sterile, isotonic, aqueous
  <br/>
solution containing apraclonidine hydrochloride.
  <br/>
Supplied as follows: 0.1 mL in plastic ophthalmic dispensers, packaged
  <br/>
two per pouch. These dispensers are enclosed in a foil overwrap as an
  <br/>
added barrier to evaporation.
  <br/>
0.1 mL (packaged two per pouch) NDC 82667â€‘200-01
 </paragraph>
                  <paragraph>
                     <content styleCode="bold">Storage:</content> Store at 2Â°C to 25Â°C (36Â°Fâ€‘77Â°F).
  <br/>
Protect from light.
 </paragraph>
                  <paragraph>Manufactured for:
  <br/>
Harrow Eye, LLCâ„¢
  <br/>
Nashville, TN 37205 USA
  <br/>
Revised: February 2023
 </paragraph>
               </text>
               <effectiveTime value="20230731"/>
            </section>
         </component>
         <component>
            <section ID="id_link_00f24c18-a1e9-b119-e063-6294a90a7e8d">
               <id root="01cc635d-01e8-3699-e063-6294a90a07bc"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <text>
                  <paragraph>NDC 82667-200-01
  <br/>
                     <br/>
                     <content styleCode="bold">IOPIDINEÂ®</content>
                     <br/>
(apraclonide hydrochloride ophthalmic solution)
 </paragraph>
                  <paragraph>1% as base
  <br/>
Sterile
  <br/>
CONTENTS: 12 pouches containing 2 units, 0.1mL each
  <br/>
Store at 2Â°-25Â°C (36Â°-77Â°F). Protect from light.
 </paragraph>
                  <paragraph/>
                  <paragraph>
                     <content styleCode="bold">Rx Only</content>
                  </paragraph>
                  <paragraph>
                     <br/>
                     <content styleCode="bold">HARROWÂ®</content>
                     <br/>
Manufactured for:
  <br/>
Harrow Eye, LLC,
  <br/>
Nashville, TN 37205 USA
  <br/>
Made in France
 </paragraph>
                  <paragraph/>
                  <paragraph>
                     <renderMultiMedia referencedObject="img_00f255f0-f57b-d564-e063-6294a90a7bee"/>
                  </paragraph>
                  <paragraph/>
                  <paragraph/>
               </text>
               <effectiveTime value="20230731"/>
               <component>
                  <observationMedia ID="img_00f255f0-f57b-d564-e063-6294a90a7bee">
                     <text>pouch</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="pouch.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>